Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ambrx Biopharma Inc. (AMAM)

1.775   -0.075 (-4.05%) 02-03 14:10
Open: 1.85 Pre. Close: 1.85
High: 1.92 Low: 1.7494
Volume: 252,106 Market Cap: 69(M)

Technical analysis

as of: 2023-02-03 1:44:35 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.71     One year: 3.28
Support: Support1: 1.52    Support2: 1.27
Resistance: Resistance1: 2.32    Resistance2: 2.8
Pivot: 1.97
Moving Average: MA(5): 1.88     MA(20): 2.04
MA(100): 1.34     MA(250): 2.62
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 7.2     %D(3): 8.1
RSI: RSI(14): 46.1
52-week: High: 5.11  Low: 0.37
Average Vol(K): 3-Month: 3,882 (K)  10-Days: 354 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMAM ] has closed above bottom band by 10.6%. Bollinger Bands are 55% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.92 - 1.94 1.94 - 1.94
Low: 1.74 - 1.76 1.76 - 1.77
Close: 1.83 - 1.85 1.85 - 1.87

Company Description

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Headline News

Fri, 03 Feb 2023
2023-02-03 | NYSE:AMAM | Press Release | Ambrx Biopharma Inc ... - Stockhouse

Wed, 01 Feb 2023
Should You Accumulate Ambrx Biopharma Inc - ADR (AMAM) Stock Wednesday Morning? - InvestorsObserver

Tue, 17 Jan 2023
Ambrx Biopharma: Some Promise, Much Uncertainty (NYSE:AMAM) - Seeking Alpha

Tue, 10 Jan 2023
Is Ambrx Biopharma Inc - ADR (AMAM) Stock a Smart Value Tuesday? - InvestorsObserver

Tue, 10 Jan 2023
Penny Stocks To Buy? 3 With High Short Interest To Watch This Week - Penny Stocks

Tue, 20 Dec 2022
Premarket Mover: Ambrx Biopharma Inc - ADR (AMAM) Down 5.69% - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 39 (M)
% Held by Insiders 1.038e+007 (%)
% Held by Institutions 0 (%)
Shares Short 1,880 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.564e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 487.2
Return on Equity (ttm) -24.7
Qtrly Rev. Growth 5.24e+006
Gross Profit (p.s.) 0.19
Sales Per Share 0.19
EBITDA (p.s.) -1.61
Qtrly Earnings Growth 6.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -68 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.3
Price to Book value 0
Price to Sales 9.2
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 712130
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.